A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

Completed · Phase 2 · Has a placebo group

Conditions studied: Zika Virus

In brief

This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.

Key facts

Study ID

NCT04917861

Run by

ModernaTX, Inc.

People needed

808

Starts

2021-06-07

Expected to finish

2024-07-26

Last updated by the study team

2025-09-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

• Meridian Clinical Research (Sioux City, IA) — Sioux City, Iowa, United States
• Johnson County Clin-Trials — Lenexa, Kansas, United States
• Benchmark Research - Fort Worth — Fort Worth, Texas, United States
• Clinical Research Puerto Rico, Inc. — Guayama, PR, Puerto Rico
• Ponce Medical School Foundation, Inc. — Ponce, PR, Puerto Rico
• Ponce Medical School Foundation, Inc. — Ponce, PR, Puerto Rico
• Clinical Research Puerto Rico, Inc. — San Juan, PR, Puerto Rico
• Latin Clinical Trial Center, Inc. — San Juan, PR, Puerto Rico
• GCM Medical Group, PSC — San Juan, PR, Puerto Rico
• Carribean Medical Research — San Juan, PR, Puerto Rico
• University of Puerto Rico — San Juan, PR, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.